ROSE Zur Rose Group AG

EQS-News: Cooperation between Medbase and Zur Rose: The two joint ventures between Zur Rose and Medbase will commence operations at the start of the year

EQS Group-News: Zur Rose Group AG / Key word(s): Joint Venture
Cooperation between Medbase and Zur Rose: The two joint ventures between Zur Rose and Medbase will commence operations at the start of the year

20.12.2019 / 07:00


Frauenfeld und Winterthur, 20 December 2019

Press release

Cooperation between Medbase and Zur Rose

The two joint ventures between Zur Rose and Medbase will commence operations at the start of the year

The joint ventures announced between Zur Rose and Medbase - a subsidiary of Migros - will start operations on 1 January 2020. They concern the roll-out of shop-in-shop pharmacies in Migros branches and a webshop for consumer health and personal care products respectively.

Following the successful pilot phase with the three current shop-in-shop pharmacies in Migros branches in Bern, Basel and Zurich, the two companies have agreed to extend the roll-out of the concept under the Zur Rose brand through a joint venture. To this end, the existing shop-in-shop pharmacies and the Zur Rose pharmacy at Welle 7 in Bern will be transferred to the joint venture with effect from 1 January 2020. Further shop-in-shop pharmacies are planned in the Migros supermarket in Crissier in the canton of Vaud and in the Tivoli shopping centre in Spreitenbach. Additional locations are being evaluated.

The shop-in-shop pharmacies provide a convenient way for customers to combine their daily shopping in Migros with buying medicines and pharmacy-exclusive healthcare and cosmetic products, while also enjoying the advantages of the ability to shop across channels.

The second joint venture between Medbase and Zur Rose is a collaboration in e-commerce: from the start of next year the two partners will be operating a joint webshop for consumer health and personal care products, again under the Zur Rose brand (-shop.ch). In the medium term the company intends to operate the webshop as a marketplace where other partners can also offer their products.

Pictures:

The following link provides print-quality images that can be used for media reporting: /websites/zurrosegroup/German/201010/medienmitteilung.html?newsID=1634399

 

Contact:

Pascale Ineichen, Corporate Communications Zur Rose Suisse AG
Direct line 8 | Email

Sonja Benninger, Marketing/Communications Medbase Group
Direct line 6 | Email

Zur Rose Suisse AG

Zur Rose Suisse AG, a subsidiary of Zur Rose Group AG, is one of Switzerland's leading mail-order pharmacies and medical wholesalers. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management and actively promotes its positioning as a comprehensive, integrated cross-service healthcare platform. The creation of added value and a pronounced patient orientation make it an important strategic partner for service providers, payers and industry.
The Zur Rose Group is Europe's largest mail-order pharmacy. For further information please see zurrosegroup.com.

Medbase Group

The Medbase Group is Switzerland's leading provider of outpatient healthcare services, operating medical centres in over 50 locations. Patients receive holistic care covering everything from prevention to acute medicine and rehabilitation. Some 300 general practitioners and specialists and over 360 therapists work in coordination across disciplines within the Group. For companies, Medbase Corporate Health offers customised consultancy services and full projects in occupational healthcare management. For further information please see



End of Corporate News


Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland
Phone: 4
Internet:
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 941043

 
End of News EQS Group News Service

941043  20.12.2019 

fncls.ssp?fn=show_t_gif&application_id=941043&application_name=news&site_id=research_pool
EN
20/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zur Rose Group AG

 PRESS RELEASE

DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the ...

DocMorris AG / Key word(s): Development of Sales DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter 21.01.2025 / 06:58 CET/CEST Frauenfeld, 21 January 2025 Press release DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter All business divisions contribute to revenue growth in 2024 OTC revenues increase by 6.7 per cent in 2024 New Rx customers grew fivefold and Rx revenue up 16.6 per cent in the fourth quarter of 2024 TeleClinic with profitable doubling of revenue in 2024 Cash position of CHF 95 million...

 PRESS RELEASE

DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im v...

DocMorris AG / Schlagwort(e): Umsatzentwicklung DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal 21.01.2025 / 06:58 CET/CEST Frauenfeld, 21. Januar 2025 Medienmitteilung DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal Alle Geschäftsbereiche tragen zum Umsatzwachstum 2024 bei OTC-Umsatz 2024 erhöht sich um 6.7 Prozent Rx-Neukunden verfünffacht und Rx-Umsatz plus 16.6 Prozent im vierten Quartal 2024 TeleClinic mit profitabler Umsatzverdoppelung in 2024 Cashbestand von CHF 95 Mio. per Ende 2024 DocM...

 PRESS RELEASE

DocMorris beschleunigt Rx-Wachstum

DocMorris AG / Schlagwort(e): Quartals-/Zwischenmitteilung DocMorris beschleunigt Rx-Wachstum 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15. Oktober 2024 Medienmitteilung DocMorris beschleunigt Rx-Wachstum Rx-Umsatzwachstum von 12.2 Prozent im dritten Quartal Beschleunigung auf über 25 Prozent in den letzten Wochen Starke Zunahme der Rx-Neukunden OTC-Wachstum von 1.9 Prozent Pablo Ros Gomez wird neuer CTO Schliessung des Logistikstandorts in Halle (DE) Das E-Rezept-Geschäft von DocMorris nimmt weiter Fahrt auf: Im dritten Quartal 2024 wuchs der Aussenumsatz mit versch...

 PRESS RELEASE

DocMorris accelerates Rx growth

DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15 October 2024 Press release DocMorris accelerates Rx growth Rx revenue growth of 12.2 per cent in the third quarter Acceleration to over 25 per cent in the last few weeks Strong increase in new Rx customers OTC growth of 1.9 per cent Pablo Ros Gomez becomes new CTO Closure of the logistics site in Halle (DE) DocMorris' e-prescription business continues to gain momentum: In the third quarter of 2024, external revenue of prescription med...

 PRESS RELEASE

DocMorris with accelerated and significant eRx growth in new customers...

DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris with accelerated and significant eRx growth in new customers, market share and revenue 11.07.2024 / 06:58 CET/CEST Frauenfeld, 11 July 2024 Press release DocMorris with accelerated and significant eRx growth in new customers, market share and revenue Tripling of new Rx customers since the introduction of CardLink Doubling and continuous increase in eRx market share since January 2024 17 per cent revenue growth of prescription medicines (Rx) compared to the previous quarter Since mid-April, the “CardLi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch